Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. B 1793
2. B 1939
3. B-1793
4. B-1939
5. E 7389
6. E-7389
7. Er 086526
8. Er-086526
9. Er-86526
10. Er086526
11. Eribulin
12. Eribulin (as Mesylate)
13. Eribulin Mesilate
14. Eribulin Monomethanesulfonate
15. Halaven
16. Nsc 707389
17. Nsc-707389
18. Nsc707389
1. Halaven
2. Eribulin Mesilate
3. 441045-17-6
4. Eribulin (mesylate)
5. Eribulin Mesylate [usan]
6. Eribulin (as Mesylate)
7. E7389
8. Eribulin Monomethanesulfonate
9. Av9u0660cw
10. Chebi:70710
11. E 7389
12. E-7389
13. Eribulin Mesilate (jan)
14. Eribulin Mesylate (usan)
15. B-1939
16. (1s,3s,6s,9s,12s,14r,16r,18s,20r,21r,22s,26r,29s,31r,32s,33r,35r,36s)-20-[(2s)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic Acid
17. Eribulin Mesilate [jan]
18. Nsc-707389
19. Er-086526
20. Unii-av9u0660cw
21. Halaven (tn)
22. B1939 Mesylate
23. E7389 Mesylate
24. Er-086526 Mesylate
25. Chembl1683544
26. Eribulin Mesylate [vandf]
27. Eribulin Mesilate [mart.]
28. Eribulin Mesilate [who-dd]
29. Ex-a4873
30. Eribulin Mesylate [ema Epar]
31. Hy-13442a
32. Eribulin Mesylate [orange Book]
33. Eribulin Monomethanesulfonate [mi]
34. D08914
35. Q27882076
36. B1939 Mesylate; E7389 Mesylate; Er-086526 Mesylate
37. (2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-2-((2s)-3-amino-2-hydroxypropyl)-3-methoxy-26-methyl-20,27-dimethylidenehexacosahydro-11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one Methanesulfonate (salt)
38. 11,15:18,21:24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3':5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5(4h)-one, 2-((2s)-3- Amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, 2r,3r,3as,7r,8as,9s,10ar,11s,12r,13ar,13bs,15s,18s,21s,24s,26r,28r,29as)-, Methanesulfonate (salt)
39. 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one Methanesulfonate
Molecular Weight | 826.0 g/mol |
---|---|
Molecular Formula | C41H63NO14S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 4 |
Exact Mass | 825.39692686 g/mol |
Monoisotopic Mass | 825.39692686 g/mol |
Topological Polar Surface Area | 209 Ų |
Heavy Atom Count | 57 |
Formal Charge | 0 |
Complexity | 1470 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 19 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Halaven |
PubMed Health | Eribulin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | HALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl... |
Active Ingredient | Eribulin mesylate |
Dosage Form | Solution |
Route | Intravenous |
Strength | 1mg/2ml (0.5mg/ml) |
Market Status | Prescription |
Company | Eisai |
2 of 2 | |
---|---|
Drug Name | Halaven |
PubMed Health | Eribulin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | HALAVEN (eribulin mesylate) Injection is a non-taxane microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesyl... |
Active Ingredient | Eribulin mesylate |
Dosage Form | Solution |
Route | Intravenous |
Strength | 1mg/2ml (0.5mg/ml) |
Market Status | Prescription |
Company | Eisai |
Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5. 1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.
Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5. 1).
L01XX41
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35948
Submission : 2021-05-27
Status : Active
Type : II
NDC Package Code : 71796-044
Start Marketing Date : 2021-11-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37054
Submission : 2023-05-29
Status : Active
Type : II
Available Reg Filing : ASMF |
NDC Package Code : 58272-208
Start Marketing Date : 2012-06-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-02-03
Pay. Date : 2021-12-17
DMF Number : 36433
Submission : 2021-11-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-09-22
DMF Number : 37559
Submission : 2023-01-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34819
Submission : 2020-08-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36628
Submission : 2022-04-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38698
Submission : 2023-12-26
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2022-02-03
Pay. Date : 2021-12-17
DMF Number : 36433
Submission : 2021-11-30
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35948
Submission : 2021-05-27
Status : Active
Type : II
ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37054
Submission : 2023-05-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-05-14
Pay. Date : 2019-03-27
DMF Number : 33425
Submission : 2019-03-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-02-08
Pay. Date : 2020-11-06
DMF Number : 35118
Submission : 2020-10-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2025-04-24
Pay. Date : 2025-04-02
DMF Number : 36566
Submission : 2021-12-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-29
Pay. Date : 2021-09-28
DMF Number : 35358
Submission : 2020-11-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36628
Submission : 2022-04-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-02-15
Pay. Date : 2022-01-11
DMF Number : 36605
Submission : 2022-01-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34819
Submission : 2020-08-06
Status : Active
Type : II
Registration Number : 304MF10030
Registrant's Address : Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China...
Initial Date of Registration : 2022-02-10
Latest Date of Registration : 2022-02-10
Registration Number : 301MF10104
Registrant's Address : 4-6-10 Koishikawa, Bunkyo-ku, Tokyo
Initial Date of Registration : 2019-12-10
Latest Date of Registration : 2019-12-10
Date of Issue : 2022-09-30
Valid Till : 2025-07-02
Written Confirmation Number : WC-0226
Address of the Firm : D-24 & D-24/1, M.I.D.C., Kurkumbh, Taluka: Daund, District. Pune-413 802, Mahara...
Date of Issue : 2022-09-16
Valid Till : 2025-12-06
Written Confirmation Number : WC-0372A2
Address of the Firm : S.No.73/1A, 74/7B,78/1B,79/1,2B,3,4B,5,6A,6B,7,80/1,2,3,4,84/1,2,3A,5A,6,7A,85/2...
Registrant Name : Korea Ezai Co., Ltd.
Registration Date : 2012-08-09
Registration Number : Su3834-1-ND
Manufacturer Name : Kashima Plant, Eisai Co., Lt...
Manufacturer Address : 22 Sunayama, Kamisu-shi, Ibaraki-ken 314-0255
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-044
Start Marketing Date : 2021-11-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
NDC Package Code : 58272-208
Start Marketing Date : 2012-06-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11071-892
Start Marketing Date : 2010-11-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11071-891
Start Marketing Date : 2010-11-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14593-949
Start Marketing Date : 2023-06-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (15kg/15kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14593-945
Start Marketing Date : 2021-03-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10g/10g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66499-0074
Start Marketing Date : 2020-11-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 61662-0019
Start Marketing Date : 2023-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 13612-0022
Start Marketing Date : 2021-05-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10g/10g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 33656-0018
Start Marketing Date : 2022-04-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.
About the Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and new modalities such as...
About the Company : ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts...
About the Company : Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the...
About the Company : Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health servic...
About the Company : Emcure Pharmaceuticals Ltd. is a fast-growing fully integrated Indian pharmaceutical company with a global presence engaged in developing, manufacturing, and marketing a broad rang...
About the Company : Established in 2010, Mac-Chem is a NMM Group company. Mac-Chem is focused on oncology and other niche specialty APIs. It supplies quality APIs to the top 15 oncology players in Ind...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Lead Product(s): Eribulin,Inapplicable
Therapeutic Area: Oncology Brand Name: Eribulin EVER Pharma
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024
Lead Product(s) : Eribulin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EVER Pharma gained EU-Approval for Advanced Cancer Treatment
Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Product Name : Eribulin EVER Pharma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2024
Details:
TQB2930 is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): TQB2930,Capecitabine,Gemcitabine,Vinorelbine Tartrate,Eribulin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 02, 2025
Lead Product(s) : TQB2930,Capecitabine,Gemcitabine,Vinorelbine Tartrate,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Details : TQB2930 is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 02, 2025
Details:
Evorpacept is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s):
Evorpacept,Trastuzumab,Paclitaxel,Capecitabine,Eribulin,Gemcitabine,Vinorelbine Tartrate,Cetuximab,Irinotecan Hydrochloride,
Therapeutic Area: Oncology
Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Protein Sponsor:
Undisclosed
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
June 06, 2025
Lead Product(s) :
Evorpacept,Trastuzumab,Paclitaxel,Capecitabine,Eribulin,Gemcitabine,Vinorelbine Tartrate,Cetuximab,Irinotecan Hydrochloride,
Therapeutic Area :
Oncology Highest Development Status :
Phase I/ Phase II Partner/Sponsor/Collaborator :
Undisclosed Deal Size : Inapplicable Deal Type : Inapplicable
ASPEN-09: Study of Evorpacept with Anti-Cancer Therapy in Advanced/Metastatic Malignancies
Details : Evorpacept is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 06, 2025
Details:
Undisclosed
Lead Product(s): Encoberminogene Rezmadenovec,Eribulin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Exelixis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 04, 2025
Lead Product(s) : Encoberminogene Rezmadenovec,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2025
Details:
Undisclosed
Lead Product(s): Melphalan,Eribulin,Vinorelbine Tartrate,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2025
Lead Product(s) : Melphalan,Eribulin,Vinorelbine Tartrate,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 13, 2025
Details:
Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.
Lead Product(s): Eribulin,Inapplicable
Therapeutic Area: Oncology Brand Name: Eribulin Mesylate-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 04, 2024
Lead Product(s) : Eribulin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection
Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.
Product Name : Eribulin Mesylate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2024
Details:
Undisclosed
Lead Product(s): Zanidatamab,Eribulin,Vinorelbine Tartrate,Gemcitabine,Capecitabine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2024
Lead Product(s) : Zanidatamab,Eribulin,Vinorelbine Tartrate,Gemcitabine,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 30, 2024
Details:
Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab
Lead Product(s): Eribulin,Inapplicable
Therapeutic Area: Oncology Brand Name: Eribulin Mesylate-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Kexing Biopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2024
Lead Product(s) : Eribulin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Kexing Biopharm
Deal Size : Undisclosed
Deal Type : Agreement
Kexing Introduces Eribulin Mesylate Injection, Expanding Overseas Product Offerings
Details : Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab
Product Name : Eribulin Mesylate-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2024
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2023
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2022
Methyl 2-((2R,4aS,6S,7R,8S,8aS)-7,8-bis((tert-buty...
CAS Number : 157322-83-3
End Use API : Eribulin
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
3,6-Anhydro-2,4,7-trideoxy-8,9-bis-O-[(1,1-dimethy...
CAS Number : 871348-24-2
End Use API : Eribulin
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
CAS Number : 157322-47-9
End Use API : Eribulin
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
(2-Furanpropanol, 5-[2-[(2S,4R,6R)-6-[[(2S,3S,4R,5...
CAS Number : 253128-10-8
End Use API : Eribulin
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
CAS Number : 157322-83-3
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 157322-47-9
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 871360-33-7
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 137688-20-1
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 1808153-91-4
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
CAS Number : 1808153-90-3
End Use API : Eribulin
About The Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and ne...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2025-07-03
Application Number : 217473
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2024-10-01
Application Number : 217250
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2025-03-04
Application Number : 218743
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : Yes
TE Code : AP
Brand Name : HALAVEN
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2010-11-15
Application Number : 201532
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2024-04-05
Application Number : 218047
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2024-07-18
Application Number : 214850
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2025-06-09
Application Number : 214310
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2025-08-05
Application Number : 218142
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
Brand Name : ERIBULIN MESYLATE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1MG/2ML (0.5MG/ML)
Approval Date : 2024-06-28
Application Number : 218281
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Halaven
Dosage Form : Inj Solution
Dosage Strength : 1mg/2ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : HALAVEN
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 0.44 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Halaven
Dosage Form : Eribulina 0.88Mg 2Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 0.88 mg 2 ml 0.44 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Halaven
Dosage Form : Injection fluid, resolution
Dosage Strength : 0.44 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Canada
Brand Name : HALAVEN
Dosage Form : SOLUTION
Dosage Strength : 0.5MG/ML
Packaging : 2ML
Approval Date :
Application Number : 2377438
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : NAT-ERIBULIN
Dosage Form : SOLUTION
Dosage Strength : 0.5MG/ML
Packaging :
Approval Date :
Application Number : 2539136
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Halaven
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Halaven
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Halaven
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Halaven
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Halaven
Dosage Form : INJ
Dosage Strength : 10mg
Packaging : 2X1mg/2ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 0.5MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Filed
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Filed
Dosage : Injection
Dosage Strength : 0.5MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Iran
Brand Name : Nibulin®
Dosage Form : Solution for Injection
Dosage Strength : 1MG/2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Solution for Injection
Dosage Strength : 1MG/2ML
Brand Name : Nibulin®
Approval Date :
Application Number :
Registration Country : Iran
https://www.pharmacompass.com/radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff
02 Sep 2025
// EXPRESSPHARMA
https://www.expresspharma.in/glenmark-pharmaceuticals-to-launch-eribulin-mesylate-injection-1mg-2ml-0-5-mg-ml-single-dose-vials/
03 Jul 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217473
01 Oct 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217250
28 Jun 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218281
16 Apr 2024
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-gained-eu-approval-for-advanced-cancer-treatment/
07 Apr 2024
// INDINPHARMAPOST
https://www.indianpharmapost.com/drug-approval/gland-pharma-receives-usfda-approval-for-eribulin-mesylate-injection-15492
Global Sales Information
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 618,194
Year : 2023
Prescribers : 24
Prescriptions : 90
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 865,201
Year : 2022
Prescribers : 29
Prescriptions : 132
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 870,082
Year : 2021
Prescribers : 32
Prescriptions : 124
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 1,193,528
Year : 2020
Prescribers : 39
Prescriptions : 198
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 1,302,534
Year : 2019
Prescribers : 43
Prescriptions : 183
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 906,346
Year : 2018
Prescribers : 41
Prescriptions : 156
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 1,046,183
Year : 2017
Prescribers : 52
Prescriptions : 185
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Eisai Inc.
Eribulin Mesylate
Drug Cost (USD) : 939,226
Year : 2016
Prescribers : 45
Prescriptions : 190
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Dosage Form : Eribulina 0.88Mg 2Ml 1 Units Par...
Dosage Strength : 1 vial EV 0.88 mg 2 ml 0.44 mg/ml
Price Per Pack (Euro) : 595.79
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Dosage Form : Inj Solution
Dosage Strength : 1mg/2ml
Price Per Pack (Euro) : 225.64
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Injection fluid, resolution
Dosage Strength : 0.44 mg/ml
Price Per Pack (Euro) : 417.85
Published in :
Country : Norway
RX/OTC/DISCN :
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 359
2019 Revenue in Millions : 385
Growth (%) : -7
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 331
2020 Revenue in Millions : 344
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 316
2021 Revenue in Millions : 331
Growth (%) : -4
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 260
2022 Revenue in Millions : 316
Growth (%) : -8
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 215
2023 Revenue in Millions : 291
Growth (%) : -26
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 380
2016 Revenue in Millions : 371
Growth (%) : 3
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 365
2017 Revenue in Millions : 356
Growth (%) : 2%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 378
2018 Revenue in Millions : 377
Growth (%) : 0
Market Place
Reply
16 Aug 2024
Reply
22 Jul 2024
Reply
20 Jul 2024
Reply
24 May 2023
Reply
07 Dec 2022
Reply
30 Nov 2021
Reply
24 Feb 2021
Reply
20 Aug 2020
Reply
04 Feb 2020
Reply
19 Sep 2019
Reply
05 Sep 2025
Reply
26 Sep 2024
Reply
17 Mar 2022
Reply
17 Aug 2021
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
21
PharmaCompass offers a list of Eribulin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Eribulin manufacturer or Eribulin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eribulin manufacturer or Eribulin supplier.
PharmaCompass also assists you with knowing the Eribulin API Price utilized in the formulation of products. Eribulin API Price is not always fixed or binding as the Eribulin Price is obtained through a variety of data sources. The Eribulin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Eribulin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eribulin, including repackagers and relabelers. The FDA regulates Eribulin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eribulin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eribulin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eribulin supplier is an individual or a company that provides Eribulin active pharmaceutical ingredient (API) or Eribulin finished formulations upon request. The Eribulin suppliers may include Eribulin API manufacturers, exporters, distributors and traders.
click here to find a list of Eribulin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Eribulin DMF (Drug Master File) is a document detailing the whole manufacturing process of Eribulin active pharmaceutical ingredient (API) in detail. Different forms of Eribulin DMFs exist exist since differing nations have different regulations, such as Eribulin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Eribulin DMF submitted to regulatory agencies in the US is known as a USDMF. Eribulin USDMF includes data on Eribulin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eribulin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Eribulin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Eribulin Drug Master File in Japan (Eribulin JDMF) empowers Eribulin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Eribulin JDMF during the approval evaluation for pharmaceutical products. At the time of Eribulin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Eribulin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Eribulin Drug Master File in Korea (Eribulin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eribulin. The MFDS reviews the Eribulin KDMF as part of the drug registration process and uses the information provided in the Eribulin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Eribulin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eribulin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Eribulin suppliers with KDMF on PharmaCompass.
A Eribulin written confirmation (Eribulin WC) is an official document issued by a regulatory agency to a Eribulin manufacturer, verifying that the manufacturing facility of a Eribulin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eribulin APIs or Eribulin finished pharmaceutical products to another nation, regulatory agencies frequently require a Eribulin WC (written confirmation) as part of the regulatory process.
click here to find a list of Eribulin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eribulin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eribulin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eribulin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eribulin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eribulin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eribulin suppliers with NDC on PharmaCompass.
Eribulin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eribulin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eribulin GMP manufacturer or Eribulin GMP API supplier for your needs.
A Eribulin CoA (Certificate of Analysis) is a formal document that attests to Eribulin's compliance with Eribulin specifications and serves as a tool for batch-level quality control.
Eribulin CoA mostly includes findings from lab analyses of a specific batch. For each Eribulin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eribulin may be tested according to a variety of international standards, such as European Pharmacopoeia (Eribulin EP), Eribulin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eribulin USP).